TuisNOTA ā¢ FRA
add
Novartis AG
Vorige sluiting
ā¬95,00
Dagwisseling
ā¬94,60 - ā¬94,60
Jaarwisseling
ā¬85,60 - ā¬108,50
Markkapitalisasie
215,60Ā mjd USD
Gemiddelde volume
64,00
P/V-verhouding
-
Dividend-opbrengs
-
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 13,17Ā mjd | 8,93% |
Bedryfskoste | 5,52Ā mjd | -24,45% |
Netto inkomste | 3,19Ā mjd | 81,09% |
Netto winsgrens | 24,21 | 66,28% |
Wins per aandeel | 2,06 | 18,39% |
EBITDA | 5,50Ā mjd | 88,62% |
Effektiewe belastingkoers | 5,91% | ā |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 13,85Ā mjd | 8,08% |
Totale bates | 103,52Ā mjd | -8,14% |
Totale aanspreeklikheid | 60,08Ā mjd | -19,30% |
Totale ekwiteit | 43,44Ā mjd | ā |
Uitstaande aandele | 2,00Ā mjd | ā |
Prys om te bespreek | 4,38 | ā |
Opbrengs op bates | 10,97% | ā |
Opbrengs op kapitaal | 15,05% | ā |
Kontantvloei
Netto kontantverandering
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 3,19Ā mjd | 81,09% |
Kontant van bedrywe | 6,29Ā mjd | 16,88% |
Kontant van beleggings | -374,00Ā m | 83,09% |
Kontant van finansiering | -382,00Ā m | 54,09% |
Netto kontantverandering | 5,71Ā mjd | 275,39% |
Beskikbare kontantvloei | 4,55Ā mjd | -63,57% |
Meer oor
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, ānovae artesā.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Gestig
29 Feb. 1996
Hoofkwartier
Webwerf
Werknemers
76Ā 057